Quick Takeaways
- ENTX - Entera Bio Ltd. has 19 insiders with reported activity on this page.
- Net insider value flow over the last year: +$140,882.
- Recent transaction rows are available for direct filing-level review.
Insider Transactions Reported by 19 Insiders of Entera Bio Ltd.
- Symbol
- ENTX on Nasdaq
- Location
- Jerusalem
What Changed
- Buy value: $140,882; sell value: $0.
- Net share flow: +101,500.
Why This Matters
- This page gives a plain-language issuer insider context before you inspect transaction-level evidence.
- Use the filing links below to verify timestamps, codes, and ownership impacts directly from SEC forms.
Source Evidence
Filed on Form 4
See Original Filing
Issuer insider activity is sourced from SEC Forms 3, 4, and 5.
Insider trading overview
Last 12 monthsNet insider flow leans to buying over the last 12 months. Net value: +$140,882.
Buys
$140,882
Shares: 101,500
Insiders: 5
Sells
$0
Shares: 0
Insiders: 0
Net
+$140,882
Shares: +101,500
Insiders: 5
| Window (months) | Buy shares | Sell shares | Buy $ | Sell $ | Net $ |
|---|---|---|---|---|---|
| 0-3 | 90,500 | 0 | $120,970 | $0 | +$120,970 |
| 3-6 | 11,000 | 0 | $19,912 | $0 | +$19,912 |
| 6-9 | 0 | 0 | $0 | $0 | $0 |
| 9-12 | 0 | 0 | $0 | $0 | $0 |
Entera Bio Ltd. executives and other stock owners filed with the SEC include:
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| Knoll Capital Management, LLC | 10%+ Owner | $5,534,275 | Mixed | 14 Nov 2024 | ||
| Gerald M. Lieberman | Director | $823,723 | Mixed | 01 Jan 2026 | ||
| Miranda Jayne Toledano | Chief Executive Officer, Director | $772,186 | +$19,912 | +2.6% | Filing P/S | 29 Dec 2025 |
| Phillip Schwartz | President of R&D, Director | $601,336 | Mixed | 20 Jan 2022 | ||
| Dana Yaacov-Garbeli | Chief Financial Officer | $232,876 | Mixed | 16 Jul 2025 | ||
| Sean Ellis | Director | $231,360 | +$34,620 | +18% | Filing P/S | 05 Mar 2026 |
| Gregory Burshtein | Chief of R&D | $208,970 | Mixed | 16 Jul 2025 | ||
| Yonatan Malca | Director | $185,024 | Mixed | 01 Jan 2026 | ||
| Gerald M. Ostrov | Director | $180,820 | Mixed | 01 Jan 2026 | ||
| Hillel Galitzer | Chief Operating Officer | $153,974 | Mixed | 28 Apr 2025 | ||
| Geno J. Germano | Director | $52,000 | +$55,800 | +107% | Filing P/S | 09 Mar 2026 |
| Steven D. Rubin | Director | $22,350 | +$19,450 | +671% | Filing P/S | 12 Feb 2026 |
| Spiros Jamas | Chief Executive Officer | $9,900 | Mixed | 18 Jan 2022 | ||
| Ramesh Ratan | U.S.based CFO | $9,900 | Mixed | 19 Jan 2022 | ||
| Haya Taitel | Director | +$11,100 | Mixed | 10 Feb 2026 | ||
| Ron Mayron | Director | Mixed | 01 Jan 2024 | |||
| Roger Garceau | Director | Mixed | 01 Jan 2024 | |||
| Leslie Velka Gautam | Chief Business Officer | Mixed | 08 May 2025 | |||
| Arthur C. Santora II | Chief Medical Officer | Mixed | 24 Apr 2023 |
Top shareholders of Entera Bio Ltd. (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| Knoll Capital Management, LLC |
13F
3/4/5
|
Company · 10%+ Owner |
13%
|
5,881,879
|
$11,410,845 | — | 31 Dec 2025 | |
| OPKO HEALTH, INC. |
13D/G
|
— |
8.1%
|
3,685,226
|
$8,660,281 | $0 | 16 Mar 2025 | |
| Point72 Asset Management, L.P. |
13F
13D/G
|
Company |
2.6%
from 13D/G
|
1,193,653
|
$2,315,687 | — | 31 Dec 2025 | |
| MARSHALL WACE, LLP |
13F
|
Company |
1.4%
|
627,330
|
$1,217,020 | — | 31 Dec 2025 | |
| Schonfeld Strategic Advisors LLC |
13F
|
Company |
1.3%
|
596,585
|
$1,157,374 | — | 31 Dec 2025 | |
| Gerald M. Lieberman |
3/4/5
|
Director |
—
mixed-class rows
|
406,668
mixed-class rows
|
$823,723 | — | 01 Jan 2026 | |
| Miranda Jayne Toledano |
3/4/5
|
Chief Executive Officer, Director |
—
mixed-class rows
|
926,575
mixed-class rows
|
$772,186 | +$19,912 | 29 Dec 2025 | |
| Phillip Schwartz |
3/4/5
|
President of R&D, Director |
—
class O/S missing
|
607,410
|
$601,336 | — | 20 Jan 2022 | |
| Parkman Healthcare Partners LLC |
13F
|
Company |
0.6%
|
275,073
|
$533,642 | — | 31 Dec 2025 | |
| NORTHERN TRUST CORP |
13F
|
Company |
0.33%
|
148,668
|
$288,416 | — | 31 Dec 2025 | |
| Seven Fleet Capital Management LP |
13F
|
Company |
0.3%
|
135,318
|
$262,517 | — | 31 Dec 2025 | |
| Dana Yaacov-Garbeli |
3/4/5
|
Chief Financial Officer |
—
mixed-class rows
|
243,047
mixed-class rows
|
$232,876 | — | 16 Jul 2025 | |
| Sean Ellis |
3/4/5
|
Director |
—
mixed-class rows
|
221,603
mixed-class rows
|
$231,360 | +$34,620 | 05 Mar 2026 | |
| RENAISSANCE TECHNOLOGIES LLC |
13F
|
Company |
0.24%
|
108,001
|
$209,522 | — | 31 Dec 2025 | |
| Gregory Burshtein |
3/4/5
|
Chief of R&D |
—
mixed-class rows
|
301,442
mixed-class rows
|
$208,970 | — | 16 Jul 2025 | |
| Yonatan Malca |
3/4/5
|
Director |
—
mixed-class rows
|
110,921
mixed-class rows
|
$185,024 | — | 01 Jan 2026 | |
| Gerald M. Ostrov |
3/4/5
|
Director |
—
mixed-class rows
|
109,162
mixed-class rows
|
$180,820 | — | 01 Jan 2026 | |
| Hillel Galitzer |
3/4/5
|
Chief Operating Officer |
—
mixed-class rows
|
190,573
mixed-class rows
|
$153,974 | — | 28 Apr 2025 | |
| JANE STREET GROUP, LLC |
13F
|
Company |
0.16%
|
74,064
|
$143,685 | — | 31 Dec 2025 | |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP |
13F
|
Company |
0.14%
|
64,910
|
$125,925 | — | 31 Dec 2025 | |
| SIGNATURE ESTATE & INVESTMENT ADVISORS LLC |
13F
|
Company |
0.1%
|
47,328
|
$91,816 | — | 31 Dec 2025 | |
| HighTower Advisors, LLC |
13F
|
Company |
0.09%
|
43,140
|
$83,692 | — | 31 Dec 2025 | |
| CITADEL ADVISORS LLC |
13F
|
Company |
0.09%
|
40,230
|
$78,046 | — | 31 Dec 2025 | |
| Geno J. Germano |
3/4/5
|
Director |
0.09%
|
40,000
|
$52,000 | +$55,800 | 09 Mar 2026 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
0.05%
|
21,136
|
$41,003 | — | 31 Dec 2025 | |
| SUPERSTRING CAPITAL MANAGEMENT LP |
13F
|
Company |
0.04%
|
17,142
|
$33,255 | — | 31 Dec 2025 | |
| BANK OF AMERICA CORP /DE/ |
13F
|
Company |
0.03%
|
15,000
|
$29,100 | — | 31 Dec 2025 | |
| GOLDMAN SACHS GROUP INC |
13F
|
Company |
0.03%
|
12,327
|
$23,914 | — | 31 Dec 2025 | |
| GSA CAPITAL PARTNERS LLP |
13F
|
Company |
0.03%
|
11,890
|
$23,000 | — | 31 Dec 2025 | |
| Steven D. Rubin |
3/4/5
|
Director |
0.03%
|
15,000
|
$22,350 | +$19,450 | 12 Feb 2026 | |
| PNC FINANCIAL SERVICES GROUP, INC. |
13F
|
Company |
0.02%
|
10,000
|
$19,400 | — | 31 Dec 2025 | |
| Ramesh Ratan |
3/4/5
|
U.S.based CFO |
—
class O/S missing
|
10,000
|
$9,900 | — | 19 Jan 2022 | |
| Spiros Jamas |
3/4/5
|
Chief Executive Officer |
—
class O/S missing
|
10,000
|
$9,900 | — | 18 Jan 2022 | |
| GROUP ONE TRADING LLC |
13F
|
Company |
0%
|
51
|
$99 | — | 31 Dec 2025 | |
| UBS Group AG |
13F
|
Company |
0%
|
17
|
$33 | — | 31 Dec 2025 | |
| Roger Garceau |
3/4/5
|
Director |
—
class O/S missing
|
108,333
|
— | — | 01 Jan 2024 | |
| Ron Mayron |
3/4/5
|
Director |
—
class O/S missing
|
108,333
|
— | — | 01 Jan 2024 | |
| Arthur C. Santora II |
3/4/5
|
Chief Medical Officer |
—
class O/S missing
|
35,000
|
— | — | 24 Apr 2023 | |
| Haya Taitel |
3/4/5
|
Director |
—
class O/S missing
|
33,505
|
— | +$11,100 | 10 Feb 2026 |
Recent Insider Transactions by Companies or Individuals for Entera Bio Ltd.
Showing up to 300 most recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | Value $ | * Price $ | Shares | Shares Owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| Geno J. Germano | ENTX | Ordinary Shares, par value NIS 0.0000769 per share | Purchase | 100% | $26,000 | $1.30 | 20,000 | 40,000 | 09 Mar 2026 | Direct |
| Sean Ellis | ENTX | Ordinary Shares, par value NIS 0.0000769 per share | Purchase | 5.61% | $12,300 | $1.23 | 10,000 | 188,098 | 05 Mar 2026 | Direct |
| Steven D. Rubin | ENTX | Ordinary Shares, par value NIS 0.0000769 per share | Purchase | 50% | $7,450 | $1.49 | 5,000 | 15,000 | 12 Feb 2026 | Direct |
| Haya Taitel | ENTX | Ordinary Shares, par value NIS 0.0000769 per share | Purchase | $11,100 | $1.48 | 7,500 | $98,479 | 10 Feb 2026 | Direct | |
| Geno J. Germano | ENTX | Ordinary Shares, par value NIS 0.0000769 per share | Purchase | $29,800 | $1.49 | 20,000 | $20,000 | 10 Feb 2026 | Direct | |
| Steven D. Rubin | ENTX | Ordinary Shares, par value NIS 0.0000769 per share | Purchase | $12,000 | $1.20 | 10,000 | 10,000 | 09 Feb 2026 | Direct | |
| Sean Ellis | ENTX | Ordinary Shares, par value NIS 0.0000769 per share | Purchase | 11.2% | $22,320 | $1.24 | 18,000 | 178,098 | 09 Feb 2026 | Direct |
| Haya Taitel | ENTX | Ordinary Shares, par value NIS 0.0000769 per share | Award | 40.7% | 26,329 | 90,979 | 01 Jan 2026 | Direct | ||
| Haya Taitel | ENTX | Stock Option (right to buy) | Award | 33,505 | 33,505 | 01 Jan 2026 | Direct | |||
| Gerald M. Ostrov | ENTX | Ordinary Shares, par value NIS 0.0000769 per share | Award | 61.2% | 28,721 | 75,657 | 01 Jan 2026 | Direct | ||
| Gerald M. Ostrov | ENTX | Stock Option (right to buy) | Award | 33,505 | 33,505 | 01 Jan 2026 | Direct | |||
| Sean Ellis | ENTX | Ordinary Shares, par value NIS 0.0000769 per share | Award | 18.8% | 25,371 | 160,098 | 01 Jan 2026 | Direct | ||
| Sean Ellis | ENTX | Stock Option (right to buy) | Award | 33,505 | 33,505 | 01 Jan 2026 | Direct | |||
| Yonatan Malca | ENTX | Ordinary Shares, par value NIS 0.0000769 per share | Award | 63.8% | 30,157 | 77,416 | 01 Jan 2026 | Direct | ||
| Yonatan Malca | ENTX | Stock Option (right to buy) | Award | 33,505 | 33,505 | 01 Jan 2026 | Direct | |||
| Gerald M. Lieberman | ENTX | Ordinary Shares, par value NIS 0.0000769 per share | Award | 12.8% | 38,294 | 338,454 | 01 Jan 2026 | Direct | ||
| Gerald M. Lieberman | ENTX | Stock Option (right to buy) | Award | 33,505 | 33,505 | 01 Jan 2026 | Direct | |||
| Miranda Jayne Toledano | ENTX | Ordinary Shares, par value NIS 0.0000769 per share | Purchase | 2.65% | $19,912 | $1.81 | 11,000 | 426,575 | 29 Dec 2025 | Direct |
| Miranda Jayne Toledano | ENTX | Ordinary Shares, par value NIS 0.0000769 per share | Award | 76.9% | 180,702 | 415,575 | 16 Jul 2025 | Direct | ||
| Miranda Jayne Toledano | ENTX | Stock Option (Right to Buy) | Award | 500,000 | 500,000 | 16 Jul 2025 | Direct | |||
| Gregory Burshtein | ENTX | Ordinary Shares, par value NIS 0.0000769 per share | Award | 35% | 26,316 | 101,442 | 16 Jul 2025 | Direct | ||
| Gregory Burshtein | ENTX | Stock Option (right to buy) | Award | 200,000 | 200,000 | 16 Jul 2025 | Direct | |||
| Dana Yaacov-Garbeli | ENTX | Ordinary Shares, par value NIS 0.0000769 per share | Award | 30.3% | 26,316 | 113,047 | 16 Jul 2025 | By A2Z Counseling Ltd. | ||
| Dana Yaacov-Garbeli | ENTX | Stock Option (right to buy) | Award | 130,000 | 130,000 | 16 Jul 2025 | Direct |
* An asterisk sign (*) next to the price indicates that the price is likely invalid.